Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1995 1
1996 1
1997 3
1998 1
2000 3
2001 3
2003 3
2004 1
2005 3
2006 4
2007 6
2008 11
2009 15
2010 12
2011 17
2012 19
2013 16
2014 10
2015 8
2016 12
2017 19
2018 21
2019 13
2020 17
2021 13
2022 10
2023 6

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Results by year

Filters applied: . Clear all
Page 1
PARP inhibitors: Synthetic lethality in the clinic.
Lord CJ, Ashworth A. Lord CJ, et al. Science. 2017 Mar 17;355(6330):1152-1158. doi: 10.1126/science.aam7344. Epub 2017 Mar 16. Science. 2017. PMID: 28302823 Free PMC article. Review.
BRCAness revisited.
Lord CJ, Ashworth A. Lord CJ, et al. Nat Rev Cancer. 2016 Feb;16(2):110-20. doi: 10.1038/nrc.2015.21. Epub 2016 Jan 18. Nat Rev Cancer. 2016. PMID: 26775620 Review.
The DNA damage response and cancer therapy.
Lord CJ, Ashworth A. Lord CJ, et al. Nature. 2012 Jan 18;481(7381):287-94. doi: 10.1038/nature10760. Nature. 2012. PMID: 22258607 Review.
Resistance to DNA repair inhibitors in cancer.
Baxter JS, Zatreanu D, Pettitt SJ, Lord CJ. Baxter JS, et al. Among authors: lord cj. Mol Oncol. 2022 Nov;16(21):3811-3827. doi: 10.1002/1878-0261.13224. Epub 2022 Jun 5. Mol Oncol. 2022. PMID: 35567571 Free PMC article. Review.
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
Van Baelen K, Geukens T, Maetens M, Tjan-Heijnen V, Lord CJ, Linn S, Bidard FC, Richard F, Yang WW, Steele RE, Pettitt SJ, Van Ongeval C, De Schepper M, Isnaldi E, Nevelsteen I, Smeets A, Punie K, Voorwerk L, Wildiers H, Floris G, Vincent-Salomon A, Derksen PWB, Neven P, Senkus E, Sawyer E, Kok M, Desmedt C. Van Baelen K, et al. Among authors: lord cj. Ann Oncol. 2022 Aug;33(8):769-785. doi: 10.1016/j.annonc.2022.05.006. Epub 2022 May 21. Ann Oncol. 2022. PMID: 35605746 Free article. Review.
A decade of clinical development of PARP inhibitors in perspective.
Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. Mateo J, et al. Among authors: lord cj. Ann Oncol. 2019 Sep 1;30(9):1437-1447. doi: 10.1093/annonc/mdz192. Ann Oncol. 2019. PMID: 31218365 Free PMC article. Review.
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Zatreanu D, Robinson HMR, Alkhatib O, Boursier M, Finch H, Geo L, Grande D, Grinkevich V, Heald RA, Langdon S, Majithiya J, McWhirter C, Martin NMB, Moore S, Neves J, Rajendra E, Ranzani M, Schaedler T, Stockley M, Wiggins K, Brough R, Sridhar S, Gulati A, Shao N, Badder LM, Novo D, Knight EG, Marlow R, Haider S, Callen E, Hewitt G, Schimmel J, Prevo R, Alli C, Ferdinand A, Bell C, Blencowe P, Bot C, Calder M, Charles M, Curry J, Ekwuru T, Ewings K, Krajewski W, MacDonald E, McCarron H, Pang L, Pedder C, Rigoreau L, Swarbrick M, Wheatley E, Willis S, Wong AC, Nussenzweig A, Tijsterman M, Tutt A, Boulton SJ, Higgins GS, Pettitt SJ, Smith GCM, Lord CJ. Zatreanu D, et al. Among authors: lord cj. Nat Commun. 2021 Jun 17;12(1):3636. doi: 10.1038/s41467-021-23463-8. Nat Commun. 2021. PMID: 34140467 Free PMC article.
The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin.
Krastev DB, Li S, Sun Y, Wicks AJ, Hoslett G, Weekes D, Badder LM, Knight EG, Marlow R, Pardo MC, Yu L, Talele TT, Bartek J, Choudhary JS, Pommier Y, Pettitt SJ, Tutt ANJ, Ramadan K, Lord CJ. Krastev DB, et al. Among authors: lord cj. Nat Cell Biol. 2022 Jan;24(1):62-73. doi: 10.1038/s41556-021-00807-6. Epub 2022 Jan 10. Nat Cell Biol. 2022. PMID: 35013556 Free PMC article.
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS. Mateo J, et al. Among authors: lord cj. N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859. N Engl J Med. 2015. PMID: 26510020 Free PMC article. Clinical Trial.
PARP inhibitor combination therapy.
Dréan A, Lord CJ, Ashworth A. Dréan A, et al. Among authors: lord cj. Crit Rev Oncol Hematol. 2016 Dec;108:73-85. doi: 10.1016/j.critrevonc.2016.10.010. Epub 2016 Oct 31. Crit Rev Oncol Hematol. 2016. PMID: 27931843 Review.
228 results